Navigation Links
Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target

KING OF PRUSSIA, Pa., Aug. 18 /PRNewswire/ -- Emerging Growth Equities, Ltd. initiates coverage of CombiMatrix Corporation (Nasdaq: CBMX) with a BUY rating and an $18.00 price target. CombiMatrix is a life sciences company focused on developing and commercializing in vitro genetic diagnostics that leverage its core CustomArray technology.

Emerging Growth Equities, Ltd., is a specialty brokerage and investment banking firm that provides high quality distribution, research and trade execution for institutional and retail clients. Emerging Growth Equities, Ltd. specializes in fulfilling the capital requirements of well-managed emerging growth companies.

Institutional investors may call their Emerging Growth Equities, Ltd. sales person for a full text of the report at 888-293-1800.

This publication is neither an offer to sell nor a solicitation to buy any securities mentioned herein. The information contained herein is based on data obtained from recognized sources that are believed to be reliable. Emerging Growth Equities, Ltd. has not independently verified the facts, assumptions and estimates contained in this report. Accordingly, no representation or warranty, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. The information contained in this report is not and does not purport to be a complete analysis of every material fact respecting any company, industry, or security.

Most of the companies Emerging Growth Equities, Ltd. follows are emerging and mid-sized growth companies whose securities typically involve a higher degree of risk and more volatility than the securities of more established companies. For these and other reasons, the investments discussed or recommended in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Transactions in securities mentioned herein may be effected only in those states where such securities are qualified for sale.

Any statements nonfactual in nature herein constitute only current opinions or estimates, represent only the current judgment of the author(s), and are subject to change without notice. This report contains forward-looking statements, which involve risks and uncertainties. Actual results may differ significantly from the results described in the forward-looking statements. Emerging Growth Equities, Ltd. (or one of its affiliates) or their partners, officers, directors, analysts, employees or customers may have an interest in the securities mentioned herein and may make purchases or sales as principal or agent of these securities, or their derivatives, while this report is in circulation. A partner, employee, analyst, officer, or director of Emerging Growth Equities, Ltd. (or one of its affiliates) may serve as a director or consultant for any company mentioned herein. Emerging Growth Equities, Ltd. (or one of its affiliates) may from time to time perform investment banking services for, or solicit investment banking business or other business from, any company mentioned herein. Additional information on the securities discussed herein is available on request.

Emerging Growth Equities, Ltd. is a member of the Financial Industry Regulatory Authority, CRD number 47040.

SOURCE Emerging Growth Equities, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017
2. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
3. Pharsight to Present at Jesup and Lamont 2008 Emerging Growth Stock Conference
4. CyberKnife Users Meeting Highlights Major Clinical Data Milestones and Emerging Trends
5. Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference
6. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
7. NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Emerging Pharmaceutical Company
8. Project on Emerging Nanotechnologies and Consumers Union collaborate on ConsumersTalkNano
9. Luminex Corporation to Present at Americas Growth Capital Emerging Growth Conference
10. Neurocrine Biosciences to Present at the A.G. Edwards Annual Emerging Growth Conference
11. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... Copper ... unless it is bound to proteins, copper is also toxic to cells. With ... Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper in the ...
(Date:11/24/2015)... 24, 2015 --> ... report "Oligonucleotide Synthesis Market by Product & Services (Primer, ... Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic ... the market is expected to reach USD 1,918.6 Million ... a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... New York , November 24, 2015 ... to a recent market research report released by Transparency ... projected to expand at a CAGR of 17.5% during ... "Non-invasive Prenatal Testing Market - Global Industry Analysis, Size, ... estimates the global non-invasive prenatal testing market to reach ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh ... Insertion points for in-line sensors can represent a weak spot where leaking process ... series of retractable sensor housings , which are designed to tolerate extreme process ...
Breaking Biology Technology:
(Date:11/11/2015)... Minn. , Nov. 11, 2015   MedNet Solutions ... entire spectrum of clinical research, is pleased to announce that ... in Clinical Trials (PCT) event, to be held November ... be able to view live demonstrations of iMedNet ... and learn how iMedNet has been able to ...
(Date:11/4/2015)... November 4, 2015 --> ... report published by Transparency Market Research "Home Security Solutions Market ... Forecast 2015 - 2022", the global home security solutions market is ... by 2022. The market is estimated to expand at ... 2015 to 2022. Rising security needs among customers at ...
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
Breaking Biology News(10 mins):